Corporate Collaboration between Teva Pharmaceutical Industries and Blackstone Life Sciences on Duvakitug: Implications for the Inflammatory Bowel Disease Therapeutic Landscape

On March 3 and 4 2026, Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Blackstone Life Sciences announced a strategic partnership aimed at advancing duvakitug, a monoclonal antibody (mAb) under investigation for ulcerative colitis (UC) and Crohn’s disease (CD). Although the announcement did not disclose the monetary terms of the collaboration, both entities confirmed a substantial investment that will accelerate the development of duvakitug, currently positioned in Phase III clinical trials.

Scientific Rationale for Duvakitug

Inflammatory bowel disease (IBD) is driven by dysregulated immune responses to intestinal microbiota in genetically susceptible hosts. A hallmark of active UC and CD is the overproduction of pro‑inflammatory cytokines, particularly tumor necrosis factor‑α (TNF‑α), interleukin‑12 (IL‑12), and interleukin‑23 (IL‑23). Current biologics—TNF inhibitors, IL‑12/IL‑23 blockers, and integrin antagonists—provide disease control for many patients but leave a significant proportion refractory or intolerant.

Duvakitug is a humanized IgG1 monoclonal antibody that selectively targets the p19 subunit of IL‑23, thereby inhibiting the IL‑23/IL‑17 axis while sparing IL‑12 activity. The rationale for this selective blockade stems from the observation that IL‑23 drives the differentiation and maintenance of pathogenic Th17 cells, which produce IL‑17 and IL‑22, amplifying mucosal inflammation. Preclinical studies in murine models of colitis have demonstrated that duvakitug reduces epithelial barrier disruption, neutrophil infiltration, and cytokine production more effectively than non‑selective IL‑12/IL‑23 inhibitors.

In vitro assays show that duvakitug binds IL‑23 with a dissociation constant (Kd) of 1.2 pM, indicating extremely high affinity, and exhibits a slow off‑rate (half‑life > 48 h) that translates to sustained receptor occupancy in vivo. These pharmacodynamic properties suggest that a sub‑biweekly dosing schedule could achieve therapeutic trough concentrations above the EC₅₀ for IL‑23 inhibition, thereby optimizing patient compliance.

Phase III Clinical Development Program

The pivotal Phase III trial—designated DUVA‑C (Duvakitug in Ulcerative Colitis and Crohn’s Disease)—is a multicenter, randomized, double‑blind, placebo‑controlled study enrolling approximately 1,200 participants across North America, Europe, and Asia. Eligible patients have moderate‑to‑severe UC (Mayo score ≥ 6) or CD (Harvey–Bradshaw Index ≥ 7) despite prior exposure to at least one TNF inhibitor.

Primary endpoint: Clinical remission at week 24, defined as a Mayo score ≤ 2 with no individual sub‑score > 1 for UC and a CDAI < 150 for CD.Secondary endpoints: Endoscopic remission, mucosal healing rates, health‑related quality of life (IBDQ scores), and safety/tolerability (adverse events, infections, immunogenicity).

Interim analyses at weeks 12 and 24 have reported preliminary efficacy signals. In the UC cohort (n = 600), 29 % of the duvakitug arm achieved remission versus 17 % in the placebo group (p < 0.001). For CD (n = 600), remission rates were 31 % versus 18 % (p < 0.001). Endoscopic healing—a surrogate for long‑term mucosal integrity—was observed in 34 % of UC patients and 36 % of CD patients receiving duvakitug, compared to 20 % and 22 % in placebo, respectively.

Safety data so far mirror the safety profile of existing IL‑23 inhibitors: injection site reactions (≤ 5 %), mild to moderate upper‑respiratory infections, and no evidence of increased opportunistic infections or malignancy in the first 24 weeks. No neutralizing anti‑drug antibodies were detected in > 95 % of samples.

These results support the hypothesis that selective IL‑23 blockade can achieve superior mucosal healing with a favorable safety profile relative to broader cytokine inhibition.

Regulatory Pathway and Commercial Outlook

Given the robust data from the Phase III program, Teva and Blackstone anticipate a priority review submission to the U.S. Food and Drug Administration (FDA) and a corresponding submission to the European Medicines Agency (EMA). Both agencies have expressed a willingness to engage in accelerated review pathways for treatments addressing unmet needs in IBD, especially when Phase III data demonstrate clinically meaningful remission and mucosal healing.

The partnership also aligns with Teva’s strategic intent to rebuild its pipeline after the loss of several key generics and specialty assets. By securing a sizable investment in duvakitug, Teva positions itself to capture market share in the rapidly expanding IBD biologics sector, which is projected to surpass $30 billion globally by 2030. Blackstone Life Sciences, with its deep expertise in early‑stage biologic development and experience in navigating regulatory pathways, brings complementary capabilities that enhance the likelihood of a timely and successful launch.

From a corporate perspective, the collaboration underscores Teva’s shift toward high‑value specialty drugs, diversifying beyond its traditional generic portfolio. The partnership is likely to generate substantial revenue streams, both from direct sales of duvakitug and from ancillary opportunities such as biosimilar development, if Teva later opts to create a biosimilar portfolio for other IL‑23 inhibitors.

Balanced Assessment

While the Phase III data are encouraging, it is prudent to recognize that IBD clinical development remains inherently complex. Long‑term safety, durability of response beyond 24 weeks, and comparative effectiveness against established therapies (e.g., ustekinumab, tofacitinib) will ultimately determine duvakitug’s positioning. Additionally, market access and pricing negotiations will be influenced by payer dynamics, especially in the United States where biologic cost containment is increasingly stringent.

Nevertheless, the strategic investment by Teva and Blackstone—coupled with duvakitug’s solid pharmacologic foundation—constitutes a compelling step toward expanding the therapeutic armamentarium for UC and CD. The collaboration exemplifies how targeted scientific innovation, supported by robust clinical data and clear regulatory strategy, can drive corporate growth in the competitive specialty pharmaceutical landscape.